Efficacy of RCDOP regimen in the treatment of patients with diffuse large B-cell lymphoma.
10.3760/cma.j.issn.0253-2727.2018.06.010
- Author:
Yi Wen CAO
1
,
2
;
Qing SHI
;
Mu Chen ZHANG
;
Peng Peng XU
;
Shu CHEN
;
Wei Li ZHAO
;
Li WANG
Author Information
1. State Key Laboratory of Medical Genomics
2. Shanghai Institute of Hematology, Shanghai Rui Jin Hospital, Shanghai 200025, China.
- Publication Type:Journal Article
- Keywords:
Antineoplastic combined chemotherapy protocols;
Lymphoma, large B-cell, diffuse;
Prognosis;
Tumor burden
- MeSH:
Antineoplastic Combined Chemotherapy Protocols/therapeutic use*;
Cyclophosphamide;
Doxorubicin;
Humans;
Lymphoma, Large B-Cell, Diffuse/drug therapy*;
Prednisone;
Prognosis;
Treatment Outcome;
Vincristine
- From:
Chinese Journal of Hematology
2018;39(6):485-490
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To investigate the efficacy of RCDOP (Rituximab, cyclophosphamide, liposome doxorubicin, vincristine and prednisone) regimen in patients with de novo diffuse large B-cell lymphoma (DLBCL), especially in those patients with multiple extra-nodal involvement or Bulky diseases. Methods: A total of 87 newly diagnosed DLBCL patients who received RCDOP regimen from October 2012 to October 2017 were enrolled into this study. Survival functions were estimated using the Kaplan-Meier method and compared by the log-rank test, and χ(2) tests were used for categorical data. Results: Among the 87 DLBCL patients treated with RCDOP regimen, 81 patients achieved complete remission (CR) or partial remission (PR), with ORR as 93.1%. Patients were further classified into groups, according to the risk factors, such as IPI scores, multiple extra-nodal involvement, bulky disease, age>60, tumor Ki-67>80%, elevated serum LDH level and advanced Ann Arbor stage. The progression-free survival (PFS, P=0.084) and overall survival (OS, P=0.515) had no statistical difference among the IPI low risk (0-1 score) group, intermediate risk (2-3 scores) group and high risk (4-5 scores) group. Similarly, no statistical difference were fou nd in PFS and OS of patients with extra-nodal involvements ≥2 (P=0.303 and P=0.624), with bulky disease (P=0.518 and P=0.466), with age>60 (P=0.600 and P=0.183), with elevated serum LDH level (P=0.054 and P=0.880), with advanced Ann Arbor stage (P=0.075 and P=0.286), and with tumor Ki-67 over 80% (P=0.190 and P=0.109), when compared with those of patients without these risk factors. Conclusion: RCDOP can improve the therapeutic effect and prognosis of DLBCL patients with certain high risk factors, such as intermediate and high IPI risks, multiple extra-nodal involvements, bulky disease, age over 60, elevated LDH level, advanced Ann Arbor stage and tumor Ki-67 over 80%.
